Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation

被引：48

作者：

Ghadimi, Kamrouz ^{[1
,2
]}

Dombrowski, Keith E. ^{[3
]}

Levy, Jerrold H. ^{[1
,2
]}

Welsby, Ian J. ^{[1
,2
]}

机构：

[1] Duke Univ, Med Ctr, Div Cardiothorac Anesthesiol, Durham, NC USA

[2] Duke Univ, Med Ctr, Div Crit Care Med, Durham, NC USA

[3] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA

来源：

EXPERT REVIEW OF HEMATOLOGY | 2016年 / 9卷 / 02期

关键词：

Morpholines; Thiophenes; Andexanet alfa; Factor Xa inhibitors; Prothrombinase; Hemostasis; Thrombosis; Thrombin Generation; Apixaban; Rivaroxaban; PROTHROMBIN COMPLEX CONCENTRATE; VITAMIN-K; INTRACEREBRAL HEMORRHAGE; ORAL ANTICOAGULANTS; MANAGEMENT; RIVAROXABAN; GUIDELINES; WARFARIN; SOCIETY; PLASMA;

D O I：

10.1586/17474086.2016.1135046

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The molecule is a recombinant protein analog of factor Xa that binds to Factor Xa inhibitors and antithrombin: LMWH complex but does not trigger prothrombotic activity. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. Further trials are underway to examine its safety and efficacy in the population of patients experiencing FXa inhibitor-related bleeding.

引用

页码：115 / 122

页数：8

共 32 条

[1] Practice Guidelines for Perioperative Blood Management An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management
不详
[J]. ANESTHESIOLOGY, 2015, 122 (02) : 241 - 275
[2] [Anonymous], ASH ANN M ABSTR
[3] [Anonymous], 24 C INT SOC THROMB
[4] Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
Ansell, Jack E.
Bakhru, Sasha H.
Laulicht, Bryan E.
Steiner, Solomon S.
Grosso, Michael
Brown, Karen
Dishy, Victor
Noveck, Robert J.
Costin, James C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (22) : 2141 - 2142
[5] The role of prothrombin complex concentrates in reversal of target specific anticoagulants
Babilonia K.
Trujillo T.
[J]. Thrombosis Journal, 12 (1)
[6] Guidelines on oral anticoagulation (warfarin): third edition - 2005 update
Baglin, TP
Keeling, DM
Watson, HG
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2006, 132 (03) : 277 - 285
[7] Warfarin reversal: consensus guidelines on behalf of the Australasian Society of Thrombosis and Haemostasis
Baker, RI
Coughlin, PB
Gallus, AS
Harper, PL
Salem, HH
[J]. MEDICAL JOURNAL OF AUSTRALIA, 2004, 181 (09) : 492 - +
[8] Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Beyer-Westendorf, Jan
Foerster, Kati
Pannach, Sven
Ebertz, Franziska
Gelbricht, Vera
Thieme, Christoph
Michalski, Franziska
Koehler, Christina
Werth, Sebastian
Sahin, Kurtulus
Tittl, Luise
Haensel, Ulrike
Weiss, Norbert
[J]. BLOOD, 2014, 124 (06) : 955 - 962
[9] Crowther M, 2014, EUR HEART J, V35, P137
[10] Crowther M, 2013, 55 AM SOC HEM ANN M

← 1 2 3 4 →